Request Consultation
search-icon
Request Consultation

Advanced Protein Biomarkers

Utilizing advanced proteomic technology, Provista Diagnostics has developed Videssa® Breast, the first blood test of its kind that detects and analyzes multiple types of tumor protein biomarkers for improved cancer detection.  Unlike other liquid biopsy technologies, such as circulating tumor cells and cell-free DNA, breast cancer proteins are more abundant in the blood, offering a more effective approach for cancer detection.

ProteoMark Technology

Videssa Breast uses proprietary ProteoMark® Technology to examine multiple Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs) associated with cancer. The combination of these biomarkers with patient clinical data, generates a unique Videssa Breast protein signature that detects breast cancer in the body. For additional information on Provista’s ProteoMark Technology, watch the video or download our free eBook for a more in-depth discussion.

eBook: Unlocking the Power of Proteins: Why Protein Biomarkers Are the Key to Improving Cancer Detection

Learn more about the important role proteins play in detecting breast cancer and the development of Videssa Breast.

Download Now

Proteomics.png

The Specificity of Tumor-Associated Autoantibodies

  • Tumor-Associated Autoantibodies (TAAbs) are highly specific to particular cancers
  • TAAbs are generated by the immune system in response to a tumor
  • Leading research institutions screened more than 4,988 tumor antigens and through multiple clinical studies identified the top 28 TAAbs for early breast cancer detection + 9 TAAbs identified in literature research
  • Videssa Breast’s unique signature incorporates 20 TAAbs
TAAb Funnel 2-227-18-01.png
SPB Funnel 2-227-18-01.png

The Sensitivity Serum Protein Biomarkers

  • Serum Protein Biomarkers (SPBs) are highly sensitive in breast cancer detection
  • Breast tumors secrete SPBs into the bloodstream or are triggered by local microenvironment in response to cancer
  • Rigorous scientific discovery and clinical trials screened 53 SPBs known to be associated with breast cancer and identified the top 11 SPBs that provide the highest sensitivity for breast cancer detection + 3 SPBs identified in literature research
  • Videssa Breast’s unique signature incorporates 9 SPBs

Biology-Driven Detection:

Videssa Breast Signature in the Hallmarks of CancerHallmarks_of_Cancer_Image_HIGH_RESOLUTION_FINAL_07-25-16-01.jpg

  • Researchers describe 10 “Hallmarks of Cancer” that characterize the breakdown of healthy cells which can lead to cancer
  • Videssa Breast’s comprehensive protein signature includes biomarkers involved in 8 of the 10 Hallmarks of Cancer, ensuring accurate breast cancer detection
  • In trials published to date, all breast cancers were identified at an early state